X

Trial Profile

A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 12 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Riociguat (Primary)
Indications Pulmonary hypertension; Sarcoidosis
Focus Therapeutic Use
Acronyms RioSAPH

Most Recent Events

04 Aug 2021 Primary endpoint (Time until clinical worsening) has been met according to the results published in the Chest
04 Aug 2021 Results published in the Chest
19 May 2021 Status has been changed from recruiting to completed, as pe Results presented at the 117th International Conference of the American Thoracic Society

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com